InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $1.535 0.37 (31.76%)+
Announcement
Release
7 May 2026 9:03AM
Price at Release
$1.165
Full Release
download
Summary
PYC Therapeutics Limited has initiated a Phase 1b Multiple Ascending Dose (MAD) clinical trial for its drug candidate PYC-003, aimed at treating Polycystic Kidney Disease (PKD). The trial will assess the safety and tolerability of PYC-003 in a repeat dose setting, as well as evaluate various efficacy endpoints such as urinary PC1 protein levels, total kidney volume on MRI, and the estimated glomerular filtration rate. The commencement of this trial follows the completion of dosing for the first patient, marking a significant step in the clinical development pathway for PYC-003. The company anticipates presenting data from this study in CY27, with the Phase 1a Single Ascending Dose (SAD) study data expected in CY26. The ongoing trials are part of PYC's broader effort to develop precision RNA therapies for patients with genetic diseases lacking treatment options.
Key Points
  • Initiation of Phase 1b Multiple Ascending Dose (MAD) trial for PYC-003
  • PYC-003 targets Polycystic Kidney Disease (PKD)
  • First patient dosing in the MAD study completed
  • Trial to assess safety, tolerability, and efficacy endpoints
  • Data presentation expected in CY27
  • Part of PYC's precision RNA therapy development
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.